NCT05988034 is a Phase 1 clinical trial of Avacopan in Electrocardiography, sponsored by Amgen.

Who is sponsoring NCT05988034?

NCT05988034 is sponsored by Amgen.

What drugs are being tested in NCT05988034?

Interventions in NCT05988034: Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin.

What condition does NCT05988034 study?

NCT05988034 studies Electrocardiography.

Is NCT05988034 still recruiting?

NCT05988034 is currently completed. Last updated 14 August 2023.

Last reviewed 2023-08-14 · How we verify

NCT05988034

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

Completed Phase 1 Last updated 14 August 2023

What this trial tests

Phase 1 trial testing Avacopan in Electrocardiography in 58 participants. Completed in 31 March 2020.

Timeline

8 November 2019

Primary endpoint
22 January 2020

31 March 2020

Quick facts

Lead sponsor	Amgen
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	58
Start date	8 November 2019
Primary completion	22 January 2020
Estimated completion	31 March 2020
Sites	1 location across United States

Drugs / interventions tested

Avacopan (AVACOPAN) — full drug profile →
Moxifloxacin (moxifloxacin) — full drug profile →
Placebo for avacopan — full drug profile →
Placebo for moxifloxacin — full drug profile →

Conditions studied

Electrocardiography — all drugs for Electrocardiography →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 60, any sex, with Electrocardiography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the effects of therapeutic and supratherapeutic doses of avacopan on the heart rate corrected QT interval, using Fridericia's formula (QTcF).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants.
Miao S, Staehr P, Tai E, Darpo B, et al · · 2024 · cited 4× · PMID 38973157 · DOI 10.1111/cts.13878
Functional Roles of the Complement Immune System in Cardiac Inflammation and Hypertrophy.
Hok KD, Rich HE, Shadid A, Gunamalai L, et al · · 2025 · cited 2× · PMID 41155225 · DOI 10.3390/ijms26209931

Verify or expand the search:

Other trials of Avacopan

Trials testing the same drug.

NCT07373262 — Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement · Phase 3 · not yet recruiting
NCT06676579 — Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) · Phase 2 · recruiting
NCT06321601 — Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Ye · Phase 3 · recruiting
NCT06468826 — A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) · Phase 1 · completed
NCT06072482 — A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis · Phase 4 · recruiting

Other recruiting trials for Electrocardiography

Currently open trials in the same condition.

NCT07163767 — Acute Myocardial Infarction Prediction Using Artificial Intelligence Applied to Electrocardiogram Images · active not recruiting
NCT06434870 — Effect of Spinal Anesthesia in Elective Cesarean Cases on Frontal QRS Angle in Anemic and Non-Anemic Patients · recruiting
NCT05893459 — Beneficial or Fostering Future Struggles (B.F.F.s)? Characterizing the Role of Friends in the Development of 13- to 17-Y · NA · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05988034 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 14 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05988034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing